U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07783802) titled 'A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event' on Aug. 21.
Brief Summary: The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event.
Participation in the study will last about 9 months.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Atherosclerosis
Cardiovascular Disease
Obesity
Hypertension
Diabetes Mellitus, Type 2
Renal Insufficiency, Chronic...